NY-AQARA
5.1.2023 15:01:57 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, is set to expand its product portfolio in 2023 with the addition of innovative sensors, smart door locks, video doorbells and LED strips. Committed to providing seamless connected home experiences to millions of global users, Aqara continues to enrich its offerings with latest smart home technologies and new device types.
Video Doorbell G4 is complementary to Aqara’s indoor home cameras, and together these cameras help users to keep an eye on their homes, families and visitors anytime, anywhere. This doorbell allows highly flexible installation as it can be battery-powered or wired for continuous power. It not only supports HomeKit Secure Video and local streaming to Amazon and Google smart displays, but it will also work with Matter after the Matter specification for cameras is ready. The G4 features local, AI-enabled facial recognition, which can trigger different automations depending on the person, and the device also includes both the 7-day free cloud storage and the optional local storage via a microSD card.
Presence Sensor FP2 is a revolutionary addition to the Company’s wide-ranged sensor lineup. Based on the millimeter wave (mmWave) radar technology, the FP2 detects human presence even when the person is sitting still. It enables zone positioning, which allows users to define different zones within a room such as the bed, the dresser, or the sofa area, and the presence in each of these individual zone can trigger different automations for a more customized experience. Other features include multi-person detection, fall-detection and a built-in light sensor.
Smart Lock U100 is the first deadbolt lock from Aqara, offering a secure and convenient home access solution that can be seamlessly integrated into modern smart homes. The U100 lock is one of the few smart locks in the market that is compatible with HomeKit and supports the home key feature in Apple Wallet. Other access authentication options include fingerprints, passwords, Aqara Home app, NFC cards, and mechanical keys. Based on the Zigbee protocol, the U100 supports Matter via a compatible Aqara hub.
LED Strip T1 is a multipurpose RGB CCT lightstrip that is intended to enrich smart lighting experiences for Aqara users. It produces up to 16 million vibrant colors and tunable white light, and is addressable with gradient effects. HomeKit, Alexa and Google Home are supported, and Matter support via a compatible Aqara hub is expected to be added after its launch. The LED strip is Zigbee-based which means lower power consumption as well as less congested home Wi-Fi network, and it also serves as a repeater that enhances the Zigbee network.
These devices from Aqara will become available for purchase in the following months. For more information of these products, please check a demonstrative video here.
Committed to enabling seamless user experiences, Aqara has been working to integrate Matter into its existing and new devices. In 2023 new OTA updates will be pushed to Aqara hubs - beginning from the M2 - so that they can serve as Matter bridges and connect Aqara Zigbee devices to Matter. Moreover, the Company also confirmed a new lineup of Thread-based devices with native Matter support this year, including the Door and Window Sensor P2 and the Motion and Light Sensor P2 which are expected to hit the market in the coming months. As part of the ongoing partnerships with Aqara, both Google and Samsung are featuring these new sensors on respective booths at CES 2023, along with other Aqara devices including the Hub M2 as a Matter bridge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005437/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom